Score Overview
See the full market ranking โ
Viking Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 10.73K to $ 0.00 and net income went from -$ 39M to -$ 359M. Revenue increased in 0 of those 5 years; net income in 0.
Viking Therapeutics Inc currently holds a 5-year HDB Score of 0.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 34.02 | โ |
1 Year2025-08-12 | $ 39.86 | -14.65% |
5 Years2021-08-12 | $ 6.01 | 466.06% |
10 Years2016-08-12 | $ 1.31 | 25x |
All Time2015-04-29 | $ 8.96 | 279.69% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | All Time2015-04-29 |
|---|---|---|---|---|---|
| Price | $ 34.02 | $ 39.86 | $ 6.01 | $ 1.31 | $ 8.96 |
| Return | โ | -14.65% | 466.06% | 25x | 279.69% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 534M | $ 125M |
| 2025 | $ 0.00 | -$ 359M | $ 705M |
| 2024 | $ 0.00 | -$ 109M | $ 902M |
| 2023 | $ 0.00 | -$ 85M | $ 362M |
| 2022 | $ 0.00 | -$ 68M | $ 155M |
| 2021 | $ 10.7K | -$ 54M | $ 202M |
| 2020 | $ 10.73K | -$ 39M | $ 248M |
| 2019 | $ 0.00 | -$ 25M | $ 275M |
| 2018 | $ 0.00 | -$ 22M | $ 301M |
| 2017 | $ 0.00 | -$ 20M | $ 20M |
| 2016 | $ 0.00 | -$ 14M | $ 13M |
| IPO2015 | $ 0.00 | -$ 23M | $ 14M |
Explore beyond VKTX
You're looking at Viking Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score โ 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
Explore other companies
- Celldex Therapeutics IncCLDXยท revenue grew in 40% of years
- Co-Diagnostics, Inc. Common StockCODXยท revenue grew in 20% of years
- Xenon Pharmaceuticals IncXENEยท revenue grew in 20% of years
- Revolution Medicines IncRVMDยท revenue grew in 20% of years
- Solid Biosciences LLCSLDBยท revenue grew in 0% of years
